Millennium Management
FATE icon

Millennium Management’s Fate Therapeutics FATE Stock Holding History

Millennium Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$175K – 6091
2024
Q3 		$175K Buy
+50,000
New +$195K ﹤0.01% 5480
2022
Q1 		– Sell
-10,000
Closed -$585K – 7066
2021
Q4 		$585K Buy
+10,000
New +$567K ﹤0.01% 4910
2021
Q2 		– Sell
-10,000
Closed -$825K – 6672
2021
Q1 		$825K Buy
+10,000
New +$958K ﹤0.01% 4393

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's FATE Position: Q1 2026 in Review

Millennium Management sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 522,617 shares — an estimated $514K sold.

Millennium Management first reported a position in FATE in Q4 2013 and held it in 39 quarters. The position peaked at $52.1M in Q3 2019. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Millennium Management reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 522,617 Fate Therapeutics shares in Q1 2026, an estimated $514K.
  • Millennium Management first reported a position in Fate Therapeutics in Q4 2013 and held it in 39 quarters.
  • Millennium Management's Fate Therapeutics position peaked at $52.1M in Q3 2019.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.